Zantac (Ranitidine) Products Liability Litigation
The causation theory linking ranitidine (Zantac) and NDMA contamination to cancer is supported by FDA warnings, scientific studies, and expert testimony. NDMA, a probable carcinogen, can form in the human stomach from ranitidine under certain conditions, and exposure has been linked to increased risks of gastric, liver, and other cancers. Regulatory actions and scientific research confirm the carcinogenic potential of NDMA formed from ranitidine ([FDA, 2020](https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine); [Aldawsari et al., 2021](https://pmc.ncbi.nlm.nih.gov/articles/PMC9261846); [LWW, 2023](https://journals.lww.com/juop/fulltext/2023/10000/carcinogenic_effects_of_nitrosodimethylamine.4.aspx)).
847
Pending actions
15,018
Total actions filed
Active
Status
02/06/2020
Established
Filing deadline
The court orders and legal updates indicate that procedural deadlines are ongoing, with some responses due into late 2026. Specific filing deadlines for claims are not explicitly detailed but are governed by court schedules and procedural orders ([US Courts - MDL-2924](https://www.govinfo.gov/app/details/USCOURTS-flsd-9_20-md-02924)).
Who qualifies
Plaintiffs must demonstrate documented use of Zantac or ranitidine, with evidence of exposure including start and end dates, dosage, and frequency. Typical minimum exposure durations cited in court documents and legal analyses are at least 4-6 weeks of regular use, with some cases requiring continuous use for 3 months or more. Dosage and frequency are scrutinized, with higher doses and daily use being more likely to meet the threshold criteria.
Products involved
- Zantac
- Ranitidine
Alleged injuries
- Bladder cancer
- Liver cancer
- Stomach cancer
Bellwether trials
Bellwether trials are scheduled into 2028, with some recent trials ending in defense verdicts. Ongoing case management and settlement discussions continue, with some trials scheduled for 2028 in Connecticut ([Lawsuit Information Center](https://www.lawsuit-information-center.com/zantac-lawsuit-settlement-amount.html)).
Settlement landscape
GSK agreed to pay up to $2.2 billion to settle most state court lawsuits claiming Zantac causes cancer, covering approximately 80,000 cases. Sanofi settled Zantac lawsuits with a payout of $100 million. As of March 2026, most large settlements are finalized or in progress, with ongoing litigation and settlement discussions covering a significant portion of claims ([King Law Firm](https://www.robertkinglawfirm.com/mass-torts/zantac-lawsuit); [Lawsuit Information Center](https://www.lawsuit-information-center.com/zantac-lawsuit-settlement-amount.html)).
Lead counsel
- Names of specific attorneys or firms are not explicitly listed in the court orders or court docket summaries, but the court appointed four Co-Lead Counsel for defendants and several attorneys are involved in leadership roles, such as Anand Agneshwar, Andrew Thomas Bayman, Joseph G. Petrosinelli, and Mark Steven Cheffo, as per court docket summaries ([Courtlistener](https://www.courtlistener.com/docket/244943/parties/in-re-zantac-ranitidine-products-liability-litigation)).
This page is generated from the official JPML pending-MDL report and public court records, refreshed monthly. It is provided for attorney reference and is not legal advice.
